Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) became the darling of biotech investors. Shares skyrocketed in September 2018, after Viking announced positive results from a phase 2 clinical study of experimental drug VK2809.
Since then, though, it's been mainly downhill for Viking. Once-giddy investors realized that there's still a long way to go before VK2809 could reach the market. But is Viking Therapeutics a smart stock to buy now for investors with a long-term perspective?
Source Fool.com